Although the corona crisis has delayed Xspray’s clinical trials, a review of this significantly de-risked case leads us to raise estimates and fair value. With key catalysts due this year, we highlight the overlooked stock’s undemanding valuation – which puts HyNap-Dasa’s chance of reaching the market at just 30%, versus our 80% – and clear upside potential.